
|Videos|June 6, 2021
Investigative Treatment for Advanced Prostate Cancer Uses Targeted Approach
The investigative therapy targets a specific molecule that is generally only expressed on the prostate cancer cell, according to a recent interview.
Advertisement
New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.
Researcher Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, said any kind of cancer therapy should be as targeted as possible in order to attack cancer cells while avoiding healthy cells. Therapy with 177Lu-PSMA-617 is very precise, Morris said, because it targets a specific molecule that is generally only expressed on the prostate cancer cell.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
2
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
3
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
4
Closing the Gaps in Men’s Health Through MTM and Community Engagement
5


















































































































